Ambulance steroid shot may cut heart attack deaths, large trial underway
NCT ID NCT07478003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a single high dose of the steroid methylprednisolone, given in the ambulance before opening the blocked artery, can reduce deaths in people having a major heart attack (STEMI). About 5,200 adults will be randomly assigned to receive either the steroid or a placebo during transport. The main goal is to see if the treatment lowers the risk of dying from any cause over the following years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Methylprednisolone (a steroid drug)
What this could lead to
If it works, this could become a standard prehospital treatment to reduce deaths and heart failure after a major heart attack.
What could go wrong
This is a large phase 3 trial, but earlier phase 2 results only showed trends, not proof. Steroids have risks like infection and may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aalborg University Hospital
NOT_YET_RECRUITINGAalborg, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Odense University Hospital
NOT_YET_RECRUITINGOdense, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Skejby, Aarhus University Hospital
NOT_YET_RECRUITINGAarhus, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••